AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27428608 — intervention group
Group type: EXPERIMENTAL
Intervention: Monsel solution
Number of subjects: 145
Study 24974996 — intervention group
Group type: EXPERIMENTAL
Intervention: If-then planning
Number of subjects: 14
Study 24974996 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical instructions
Number of subjects: 14
Study 21252144 — intervention group
Group type: EXPERIMENTAL
Intervention: LPA genotype score
Number of subjects: 12236
Study 18250225 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed tracheal suction systems (TSS)
Number of subjects: 9
Study 16093520 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of posttraumatic stress (PTS) or depressive symptoms and/or high preinjury alcohol use
Number of subjects: 0
Study 16093520 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent female gender, greater levels of preinjury trauma, greater subjective distress at the time of the injury, and greater parental depressive symptoms
Number of subjects: 0
Study 12548293 — intervention group
Group type: COMPARATOR
Intervention: Maltitol (occasional consumption)
Number of subjects: 12
Study 12548293 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (occasional consumption)
Number of subjects: 12
Study 12548293 — intervention group
Group type: COMPARATOR
Intervention: Maltitol (regular consumption)
Number of subjects: 12
Study 12548293 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (regular consumption)
Number of subjects: 12
Study 11199620 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at the P‐6 Neikuan point
Number of subjects: 0
Study 11199620 — intervention group
Group type: EXPERIMENTAL
Intervention: Thumb pressure at the P‐6 point
Number of subjects: 0
Study 11199620 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐6 point stimulation
Number of subjects: 0
Study 8839823 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive mode (PRD) with step‐ramp stimulus at 12.5 to 50 degrees/s, target exposure durations (PD) from 80 to 640 ms, passive stimulation
Number of subjects: 0
Study 8839823 — intervention group
Group type: COMPARATOR
Intervention: Nonpredictive mode (RND) with randomized direction and timing of target exposure, active and passive stimulation
Number of subjects: 0
Study 8839823 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive mode (PRD)
Number of subjects: 0
Study 1394825 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV regimen (cisplatin, methotrexate, and vinblastine)
Number of subjects: 19
Study 1394825 — intervention group
Group type: EXPERIMENTAL
Intervention: M-VAC regimen (methotrexate, vinblastine, doxorubicin, and cisplatin)
Number of subjects: 19
Study 1394825 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxic symptoms in both groups
Number of subjects: 19
Study 4001759 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray 0.025% (2 X 25 mcg in each nostril twice daily)
Number of subjects: 41
Study 4001759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 31976769 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual simulation engagement
Number of subjects: 123
Study 31976769 — intervention group
Group type: COMPARATOR
Intervention: Observation of simulation engagement
Number of subjects: 123
Study 31976769 — intervention group
Group type: COMPARATOR
Intervention: Reading text vignettes
Number of subjects: 123
Study 30621529 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 4754
Study 30621529 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 4754
Study 30621529 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) in patients aged ≥75 with CHD
Number of subjects: 4754
Study 30621529 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) in patients aged <70 with CHD
Number of subjects: 4754
Study 30621529 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) in patients aged 70 to 74 with CHD
Number of subjects: 4754
Study 30621529 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) in patients aged 70 to 74 without CHD
Number of subjects: 4754
Study 30621529 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) in patients aged ≥75 without CHD
Number of subjects: 4754
Study 30621529 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) in patients aged <70 without CHD
Number of subjects: 4754
Study 29231472 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with smoothing liver and regulating qi, once a day for 6 weeks.
Number of subjects: 60
Study 29231472 — intervention group
Group type: COMPARATOR
Intervention: Lactulose oral liquid, 20 to 30 mL once a day for 6 weeks.
Number of subjects: 60
Study 25491935 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of supervised aerobic exercise
Number of subjects: 122
Study 25491935 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 122
Study 25491935 — intervention group
Group type: COMPARATOR
Intervention: Control group without crossover
Number of subjects: 122
Study 25491935 — intervention group
Group type: COMPARATOR
Intervention: Control group with crossover
Number of subjects: 122
Study 25491935 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group with <80% adherence
Number of subjects: 122
Study 25491935 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group with ≥80% adherence
Number of subjects: 122
Study 25491935 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise groups (combined)
Number of subjects: 122
Study 25491935 — intervention group
Group type: COMPARATOR
Intervention: No supervised exercise (control)
Number of subjects: 122
Study 23750468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT; Coping Cat)
Number of subjects: 488
Study 23750468 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy (sertraline)
Number of subjects: 488
Study 23750468 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment (CBT + sertraline)
Number of subjects: 488
Study 23750468 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 488
Study 21276573 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlay Ref
Number of subjects: 88
Study 21276573 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 88
Study 19453020 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy (within 72 hours)
Number of subjects: 0
Study 19453020 — intervention group
Group type: COMPARATOR
Intervention: Delayed laparoscopic cholecystectomy (after 72 hours)
Number of subjects: 0
Study 17019522 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium from milk minerals (MM) 800 mg/day
Number of subjects: 99
Study 17019522 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CC) 800 mg/day
Number of subjects: 99
Study 17019522 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 99
Study 15242535 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose nevirapine (NVP) prophylaxis
Number of subjects: 279
Study 10768912 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (group A)
Number of subjects: 41
Study 10768912 — intervention group
Group type: EXPERIMENTAL
Intervention: No ACE inhibitors (group B)
Number of subjects: 41
Study 10768912 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 41
Study 10768912 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (group A) and No ACE inhibitors (group B)
Number of subjects: 41
Study 10168910 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable augmented reality medical interfaces (WARM)
Number of subjects: 0
Study 10168910 — intervention group
Group type: EXPERIMENTAL
Intervention: Interface objects for display of real-time electrocardiographic monitoring information
Number of subjects: 0
Study 8465450 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy three times a week for three weeks
Number of subjects: 40
Study 8465450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression for twenty minutes before occupational therapy
Number of subjects: 40
Study 8465450 — intervention group
Group type: COMPARATOR
Intervention: Control group (twenty-three patients)
Number of subjects: 40
Study 3080048 — intervention group
Group type: EXPERIMENTAL
Intervention: Antivenom given by intravenous injection over 10 minutes
Number of subjects: 25
Study 3080048 — intervention group
Group type: EXPERIMENTAL
Intervention: Antivenom diluted and given as an intravenous infusion over 30 minutes
Number of subjects: 25
Study 3080048 — intervention group
Group type: COMPARATOR
Intervention: Antivenom treatment (both methods)
Number of subjects: 25
Study 3080048 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of antivenom (not specifically tested in this trial)
Number of subjects: 25
Study 30236067 — intervention group
Group type: EXPERIMENTAL
Intervention: Pen-and-paper response option (Group A)
Number of subjects: 2606
Study 30236067 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed response option (Group B)
Number of subjects: 2606
Study 30236067 — intervention group
Group type: COMPARATOR
Intervention: Electronic response option (Group C)
Number of subjects: 2606
Study 30236067 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed group (Group B)
Number of subjects: 2606
Study 27308241 — intervention group
Group type: EXPERIMENTAL
Intervention: Steri-strip dressing applied from the nose to lateral malar and cheek
Number of subjects: 64
Study 27308241 — intervention group
Group type: COMPARATOR
Intervention: Control side with steri-strip taping from the nose to medial malar and cheek
Number of subjects: 64
Study 27308241 — intervention group
Group type: EXPERIMENTAL
Intervention: Steri-strip dressing
Number of subjects: 64
Study 24268111 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 252 mg
Number of subjects: 13
Study 24268111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 24268111 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 13
Study 22717019 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 91
Study 22717019 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 91
Study 20501391 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate infusion
Number of subjects: 40
Study 20501391 — intervention group
Group type: COMPARATOR
Intervention: Propofol infusion
Number of subjects: 40
Study 18656731 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 60
Study 18656731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16635321 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine early amniotomy
Number of subjects: 0
Study 12971557 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopy
Number of subjects: 436
Study 12971557 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site OptiMAL
Number of subjects: 436
Study 12971557 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site Immunochromatographic Test (on-site ICT)
Number of subjects: 436
Study 10836011 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 0
Study 10836011 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant postoperative radiation or chemotherapy
Number of subjects: 0
Study 10836011 — intervention group
Group type: COMPARATOR
Intervention: Multimodal approach
Number of subjects: 0
Study 9369817 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled cord traction
Number of subjects: 1648
Study 9369817 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 1648
Study 1410069 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐l fenfluramine hydrochloride (60 mg)
Number of subjects: 24
Study 1410069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3882183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5-fluorouracil (5 mg kg‐1 bodyweight) for 3 months
Number of subjects: 421
Study 3882183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study 30946967 — intervention group
Group type: EXPERIMENTAL
Intervention: Black Strap Molasses (BSM) syrup (1 mL/kg body weight/day for 1 month)
Number of subjects: 92
Study 30946967 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene Glycol (PEG) syrup (1 mL/kg body weight/day for 1 month)
Number of subjects: 92
Study 28672136 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol alone (P group)
Number of subjects: 27
Study 28672136 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of propofol and midazolam (PM group)
Number of subjects: 27
Study 27240438 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation (RSD)
Number of subjects: 34
Study 27240438 — intervention group
Group type: COMPARATOR
Intervention: Control (antiarrhythmic pharmacologic therapy)
Number of subjects: 34
Study 24833688 — intervention group
Group type: EXPERIMENTAL
Intervention: High absolute risk patients with high blood pressure (SBP 147-179 mm Hg)
Number of subjects: 144
Study 24833688 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower absolute risk patients with high blood pressure
Number of subjects: 144
Study 24833688 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower blood pressure patients with high absolute risk
Number of subjects: 144
Study 24833688 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower blood pressure patients with lower absolute risk
Number of subjects: 144
Study 24833688 — intervention group
Group type: EXPERIMENTAL
Intervention: High cholesterol/high absolute risk patients
Number of subjects: 144
Study 24833688 — intervention group
Group type: EXPERIMENTAL
Intervention: High cholesterol/lower absolute risk patients
Number of subjects: 144
Study 24833688 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower cholesterol patients with high absolute risk
Number of subjects: 144
Study 24833688 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower cholesterol patients with lower absolute risk
Number of subjects: 144
Study 22476736 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing (3 times a day from postoperative day 0-5)
Number of subjects: 44
Study 22476736 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care (Control group)
Number of subjects: 44
Study 19695832 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional therapy group (NT group) received individual nutritional counseling and interventions, including oral nutritional supplements if appropriate.
Number of subjects: 36
Study 19695832 — intervention group
Group type: COMPARATOR
Intervention: Oral nutritional supplement group (ONS group) received oral nutritional supplements in addition to hospital meals without further instruction or counseling.
Number of subjects: 36
Study 19695832 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional therapy group (NT group)
Number of subjects: 36
Study 19695832 — intervention group
Group type: COMPARATOR
Intervention: Oral nutritional supplement group (ONS group)
Number of subjects: 36
Study 18840822 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 115
Study 18840822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 15841829 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational group intervention
Number of subjects: 30
Study 12432322 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume Diffusive Respirator (VDR)
Number of subjects: 64
Study 12432322 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (PCV)
Number of subjects: 64
Study 10734522 — intervention group
Group type: EXPERIMENTAL
Intervention: ParaSight-F test (PFT)
Number of subjects: 382
Study 10734522 — intervention group
Group type: COMPARATOR
Intervention: Microscopic slide readings
Number of subjects: 382
Study 8750403 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 at 0.06 micro g/kg per minute for 3 postoperative days
Number of subjects: 35
Study 8750403 — intervention group
Group type: COMPARATOR
Intervention: Control (no PGE1)
Number of subjects: 35
Study 1776410 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (ACE-inhibition)
Number of subjects: 10
Study 1776410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6130065 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (20 mg)
Number of subjects: 700
Study 6130065 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (20 mg)
Number of subjects: 700
Study 6130065 — intervention group
Group type: COMPARATOR
Intervention: Clorazepate (24 mg)
Number of subjects: 700
Study 6130065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study 31891449 — intervention group
Group type: EXPERIMENTAL
Intervention: roxadustat (initial dose, 50 or 70 mg) for 24 weeks (ESA-Naïve Study)
Number of subjects: 239
Study 31891449 — intervention group
Group type: EXPERIMENTAL
Intervention: roxadustat (initial dose, 70 or 100 mg based on prior ESA dose) for 52 weeks (ESA-Converted Study)
Number of subjects: 239
Study 31253071 — intervention group
Group type: EXPERIMENTAL
Intervention: Full major statement in TV ad
Number of subjects: 1000
Study 31253071 — intervention group
Group type: COMPARATOR
Intervention: Edited version of TV ad (only serious and actionable risks)
Number of subjects: 1000
Study 27975236 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 at 10,000 IU daily
Number of subjects: 34
Study 27975236 — intervention group
Group type: COMPARATOR
Intervention: Low-dose vitamin D3 at 1000 IU daily
Number of subjects: 34
Study 27975236 — intervention group
Group type: EXPERIMENTAL
Intervention: Both high-dose and low-dose vitamin D3
Number of subjects: 34
Study 26194253 — intervention group
Group type: EXPERIMENTAL
Intervention: Energized dissection (ED)
Number of subjects: 100
Study 26194253 — intervention group
Group type: COMPARATOR
Intervention: Non-Energized dissection (non-ED)
Number of subjects: 100
Study 24400643 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group receiving a half-day training in heart failure management and structured up-titration scheme.
Number of subjects: 0
Study 24400643 — intervention group
Group type: COMPARATOR
Intervention: Care as usual group (control).
Number of subjects: 0
Study 22348695 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich fibrin (PRF) with open-flap debridement
Number of subjects: 90
Study 22348695 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (PRP) with open-flap debridement
Number of subjects: 90
Study 22348695 — intervention group
Group type: COMPARATOR
Intervention: Open-flap debridement alone (Control)
Number of subjects: 90
Study 19219569 — intervention group
Group type: EXPERIMENTAL
Intervention: HHH therapy administered over 3-9 days
Number of subjects: 12
Study 19219569 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 12
Study 17283283 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg oral)
Number of subjects: 22
Study 17283283 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.9 mg intravenous bolus followed by 0.0102 mg/min infusion)
Number of subjects: 22
Study 17283283 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral and intravenous)
Number of subjects: 22
Study 15502053 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically relevant articles
Number of subjects: 1379
Study 15502053 — intervention group
Group type: COMPARATOR
Intervention: Journal Impact Factor
Number of subjects: 1379
Study 11680670 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole MUPS 20 mg tablet (Test)
Number of subjects: 38
Study 11680670 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole MUPS 20 mg tablet (Reference)
Number of subjects: 38
Study 11680670 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (Test and Reference)
Number of subjects: 38
Study 9636963 — intervention group
Group type: EXPERIMENTAL
Intervention: Barath Cutting Balloon (group A)
Number of subjects: 64
Study 9636963 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloons (group B)
Number of subjects: 64
Study 7866263 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine 1.0%
Number of subjects: 228
Study 7866263 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoxamine 0.02%
Number of subjects: 228
Study 7866263 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine 1.0% plus Thymoxamine 0.02%
Number of subjects: 228
Study 7866263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 2672673 — intervention group
Group type: EXPERIMENTAL
Intervention: Phadirect Strep A test
Number of subjects: 67
Study 2672673 — intervention group
Group type: COMPARATOR
Intervention: Bacteriologic investigation
Number of subjects: 67
Study 2672673 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagglutination test for SB serotyping
Number of subjects: 67
Study 616215 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg)
Number of subjects: 8
Study 616215 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg)
Number of subjects: 8
Study 616215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30535338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (4 hours of sleep between 3:00 am and 7:00 am)
Number of subjects: 15
Study 30535338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation (no sleep at all)
Number of subjects: 15
Study 30535338 — intervention group
Group type: COMPARATOR
Intervention: Regular sleep duration (8 hours of sleep between 11:00 pm and 7:00 am)
Number of subjects: 15
Study 30535338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep loss (both sleep restriction and deprivation)
Number of subjects: 15
Study 27913872 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/day of fish oil (2.4 g n-3 PUFA)
Number of subjects: 100
Study 27913872 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 100
Study 25765839 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of Erigerontis hydroxybenzenes injection (EHI)
Number of subjects: 40
Study 25765839 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of EHI
Number of subjects: 40